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The timing of extracorporeal membrane oxygenation (ECMO) initiation and its outcome in the management of
respiratory and cardiac failure have received considerable attention, but very little attention has been given to
mechanical ventilation during ECMO. Mechanical ventilation settings in non-ECMO studies have been shown to have an
effect on survival and may also have contributed to a treatment effect in ECMO trials. Protective lung ventilation
strategies established for non-ECMO-supported respiratory failure patients may not be optimal for more severe forms of
respiratory failure requiring ECMO support. The influence of positive end-expiratory pressure on the reduction of the
left ventricular compliance may be a matter of concern for patients receiving ECMO support for cardiac failure. The
objectives of this review were to describe potential mechanisms for lung injury during ECMO for respiratory or cardiac
failure, to assess the possible benefits from the use of ultra-protective lung ventilation strategies and to review
published guidelines and expert opinions available on mechanical ventilation-specific management of patients
requiring ECMO, including mode and ventilator settings. Articles were identified through a detailed search of
PubMed, Ovid, Cochrane databases and Google Scholar. Additional references were retrieved from the selected
studies. Growing evidence suggests that mechanical ventilation settings are important in ECMO patients to
minimize further lung damage and improve outcomes. An ultra-protective ventilation strategy may be optimal for
mechanical ventilation during ECMO for respiratory failure. The effects of airway pressure on right and left ventricu-
lar afterload should be considered during venoarterial ECMO support of cardiac failure. Future studies are needed
to better understand the potential impact of invasive mechanical ventilation modes and settings on outcomes.Review
Introduction
Over the past decade, the use of two distinct modalities
of extracorporeal membrane oxygenation (ECMO) for
respiratory and cardiac support in adults has increased.
Venovenous (VV)-ECMO may be initiated as a treat-
ment strategy for patients with severe acute respiratory
failure, including adult respiratory distress syndrome
(ARDS) [1-5], as a salvage therapy for patients with pro-
found gas-exchange abnormalities despite positive-
pressure ventilation. Additionally, partial extracorporeal
support systems have been suggested for less severe* Correspondence: matthieuschmidt@yahoo.fr
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2014respiratory failure as an adjunct to invasive mechanical
ventilation (MV) for patients who have excessively high
inspiratory airway pressures or who are unable to tolerate
volume-limited and pressure-limited strategies. These
devices predominately remove carbon dioxide (CO2) from
the blood and provide limited oxygenation [6-8]. Such
systems are often classified as extracorporeal carbon diox-
ide removal (ECCO2R) systems and cannot provide
complete respiratory support. VV-ECMO and ECCO2R
may now be considered management options for chronic
end-stage respiratory failure where MV is contraindicated
or undesirable; for example, as a bridge to lung transplant-
ation in patients with cystic fibrosis who need to perform
airway clearance techniques for sputum retention [9,10].
ECCO2R has also been described for chronic obstructive
pulmonary disease patients with prolonged weaning of
invasive MV [11]. Venoarterial (VA)-ECMO is a rapidly
deployable treatment option for temporary circulatoryl Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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cardiac arrest [12-14] secondary to a large number of
acute and chronic cardiac illnesses.
MV management during VV-ECMO and VA-ECMO
has received scant attention to date despite high-level
evidence to support low-tidal-volume ventilation strategies
to improve survival [15,16]. The design of randomized
controlled trials of ECMO in ARDS did not use standard-
ized protective ventilation in the interventional arm [8,17]
or in the control arm [3], which could have jeopardized
the success of the ECMO treatment in these trials. MV set-
tings may have important implications in both modes of
ECMO (that is, VV-ECMO and VA-ECMO). Patients with
the most severe forms of lung injury are likely to be par-
ticularly susceptible to ventilator-associated lung injury.
Limiting stress and strain with a volume-limited and
pressure-limited protective ventilation strategy beyond that
recommended for patients with ARDS could provide add-
itional benefit during ECMO support [4,18,19]. For patients
with severe cardiac failure supported with VA-ECMO, pul-
monary artery blood flow may be severely reduced and the
maintenance of normal alveolar ventilation might lead to
severe over-ventilation of the lungs [20]. Positive airway
pressure settings will also affect right and left ventricular
load in both VV-ECMO and VA-ECMO [21].
Brief guidelines for the use of ECMO [22] and expert
points of views [3,23] have been published, mostly dur-
ing the recent influenza A(H1N1) pandemic [24]. These
publications are based on clinician preference, experi-
ence of centers with high case volumes, previous ran-
domized trials [3] and local resource availability.
While there are extensive reviews on ECMO manage-
ment [23,25-29], there is a significant knowledge gap in
understanding the benefits and risks of MV during
ECMO. Unlike previous reviews on ECMO [23,27,29],
this review will focus on MV during ECMO. The pur-
pose is to highlight the interactions between MV, ECMO
and the pathophysiology of severe acute respiratory and
cardiac failure. A second purpose is to provide evidence
of the risks associated with MV during ECMO. Add-
itionally, this review will summarize current guidelines,
describe new strategies advocated for MV, provide
evidence-based criteria that can be used for MV during
ECMO and discuss what future studies are needed to
address the evidence gap in this area.
Physiological considerations and possible
mechanisms for harm and benefit of mechanical
ventilation during venovenous extracorporeal
membrane oxygenation
Nonpulmonary gas exchange: how much gas exchange
can extracorporeal membrane oxygenation provide?
The extent of nonpulmonary gas exchange required
during ECMO is directly related to the limitation ofpulmonary gas exchange. The amount of oxygen sup-
plied to the patient by the ECMO circuit is limited by
the maximal oxygen delivery of the membrane (that is,
membrane outlet–inlet oxygen content). The current
generation of ECMO membranes can deliver up to
450 ml oxygen/minute [30]. Actual patient oxygen de-
livery from an ECMO circuit is affected by the rate of
circuit blood flow, the hemoglobin concentration and
the oxyhemoglobin saturation of the venous blood
(partly reflecting the level of recirculation). Of note,
with VV-ECMO the circuit blood flow is related to both
the inflow cannula diameter and the cardiac output
[31]. The CO2 content in blood is higher than the oxygen
content, and is rapidly diffusible. CO2 transfer provided by
current membranes may exceed 450 ml/minute depend-
ing on the ratio of gas to blood flow in the membrane and
the CO2 partial pressure. Higher sweep gas flow and
higher CO2 partial pressure in the oxygenator blood result
in greater CO2 clearance. CO2 removal is therefore easily
controlled with sweep gas flow settings [32].
Minimizing ventilator-induced lung injury
MV can activate inflammation and worsen the pulmonary
damage of the underlying disease, leading to ventilator-
induced lung injury (VILI) [33]. Three possible causal
mechanisms of VILI may be modifiable with the use of
ECMO.
First is the alveolar strain, which represents the amount
of aerated lung receiving ventilation [34,35]. In 2000,
the ARDS Network published a multicenter random-
ized clinical trial where a strategy aimed at maintaining
plateau pressure ≤30 cmH2O with an initial tidal volume
of ≈ 6 ml/kg predicted body weight (PBW) was compared
with traditional ventilation treatment that involved an
initial tidal volume of ≈ 12 ml/kg PBW [15]. The pro-
tective ventilation, which minimizes the alveolar strain
physiological concept, was associated with a decreased
mortality of 22%. Patients at many centers who have re-
ceived ECMO for severe ARDS have a very low arterial
partial pressure of oxygen/fraction of inspired oxygen
ratio (≈50 mmHg) [1,4] and a very high acute injury
score [1,4]. In addition, these patients have a very small
area of normally aerated alveoli located in the nonde-
pendent lung, a large consolidated or nonaerated region
located in the dependent lung along the vertical axis
[36-38] and frequent infiltration of all of the four lung’s
quadrants on chest radiographs [1]. As the aerated
compartment receives the largest part of the tidal
volume [37,39], these severely unwell patients with a
large amount of collapsed lung may be exposed to VILI
despite low-tidal-volume ventilation strategies [40].
Limitation of the alveolar strain is a major concern of
patients with ARDS receiving MV during ECMO.
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tidal alveolar opening and closing (atelectrauma), defined
as the amount of collapsed lung tissue that is re-opened
during inspiration and re-collapsed during expiration
[41-43]. The challenge is to find the right ventilator set-
tings to avoid intra-tidal alveolar opening and closing
while limiting the risk of alveolar overdistension or strain
[44]. Combining a low tidal volume with high levels of
positive end-expiratory pressures (PEEP) appears to be im-
portant. Caironi and colleagues showed similar alveolar
strain after application of 15 cmH2O PEEP in two distinct
groups of 34 ARDS/acute lung injury patients (that is,
higher vs. lower percentage of potentially recruitable lung
groups) [41], suggesting that the beneficial impact of redu-
cing intra-tidal alveolar opening and closing by increasing
PEEP prevailed over the effects of increasing alveolar
strain. Of note, despite improving oxygenation [45,46] and
reducing the duration of MV [46], a strategy for setting
PEEP aimed at increasing alveolar recruitment while limit-
ing hyperinflation did not significantly reduce mortality in
ARDS [45-47].
Finally, oxygen lung toxicity from a high fraction of
inspired oxygen in lung areas with a low ventilation–
perfusion ratio might alone cause reabsorption atelec-
tasis [48-51]. Such areas are frequent in ARDS, and
Aboab and colleagues showed in mechanically venti-
lated patients with acute lung injury that the breathing
of pure oxygen leads to derecruitment, which is pre-
vented by high PEEP [52]. The challenge of MV settings
with ECMO, particularly when lung function is severely
impaired, is to minimize these pitfalls.
Physiological considerations and possible
mechanisms for harm and benefit of mechanical
ventilation during venoarterial extracorporeal
membrane oxygenation
Patients with cardiac failure receiving VA-ECMO often
have abnormal lung function that may be associated
with ARDS. Considerations from the previous section
may also apply to this group. However, the major cardio-
vascular effect associated with PEEP is reduction in
cardiac output. Although the effect of PEEP on cardiac
output is complex, the decrease is caused predominantly
by decreasing the right ventricular preload and direct
heart–lung interaction [53]. By increasing the intratho-
racic pressure, PEEP can increase pulmonary vascular
resistance, which may cause right ventricular overload and
reduced left ventricular compliance. Patients who have
received VA-ECMO with predominately right ventricular
failure can be adversely affected by high PEEP [54,55].
Conversely, patients with predominately left ventricular
failure supported with VA-ECMO may develop pulmonary
edema despite adequate systemic support and often bene-
fit from the application of high PEEP [34].Additionally, VA-ECMO may dramatically reduce pul-
monary blood flow as a result of pulmonary shunting. If
normal lung ventilation is maintained in this setting, se-
vere local alkalosis might result. To date, this potential
deleterious effect has not been widely described and
clinical consequences are still unknown. However, some
authors have suggested that decreased lung perfusion
with VA-ECMO may accelerate pulmonary vascular
thrombosis in the presence of severe lung injury [17,20].
Evidence and current recommendations
To date, animal data, observational studies and previous
randomized trials may give a physiologic rationale to
promote ultra-protective ventilation during ECMO.
Mechanical ventilation settings: tidal volume and plateau
pressure limitation
The main objectives of MV during ECMO for patients
with severe acute respiratory failure are summarized in
Figure 1. However, multiple approaches to ventilation
could be acceptable [29]. By directly removing CO2 from
the blood, ECMO enables lung-protective ventilation.
Without ECMO, difficulty maintaining adequate alveolar
ventilation is one limitation to the use of a protective
ventilation strategy – exposing patients to potential side
effects of subsequent hypercapnia, such as intracranial
pressure elevation, pulmonary hypertension, depressed
myocardial contractility and a reduction in renal blood
flow [56,57].
Using tidal volume <4 ml/kg PBW is thus recommended
with ECMO [29] and is often referred to imprecisely as
lung rest or ultra-protective ventilation [3,7]. The concept
of ultra-protective MV was suggested and investigated in
animal studies [58]. Using a rat model of acid-induced
lung injury, Frank and colleagues showed that a tidal
volume reduction from 12 to 6 to 3 ml/kg, with the same
level of PEEP (10 cmH2O), decreased pulmonary edema
and lung injury, and increased protection of the alveolar
epithelium [58]. In addition, post-hoc analysis of the ARDS
Network data in a multivariable logistic regression model
showed that lower tidal volume assignment and lower
plateau pressure quartile were significant predictors of
lower mortality [59]. Favorable outcome of patients with
ARDS treated with a strong tidal volume reduction until
1.9 ml/kg PBW with ECMO [19] and with ECCO2R [18]
have been reported. Terragni and colleagues used a system
that predominately removed CO2 to reduce tidal volume
<6 ml/kg PBW and observed a reduction of pulmonary
cytokine concentration [60]. However, survival benefit
from ultra-protective lung ventilation was not seen in a re-
cent multicenter randomized controlled trial [6]. Bein and
colleagues compared a very low tidal volume ventilation
strategy (≈ 3 ml/kg PBW) combined with ECCO2R to
lower tidal ventilation (≈ 6 ml/kg PBW) without the
Figure 1 Specifications of mechanical ventilation with extracorporeal membrane oxygenation for patients with severe acute
respiratory failure. ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; NAVA, neurally adjusted ventilator assist;
PBW, predicted body weight; PEEP, positive end-expiratory pressure.
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ber of ventilator-free days at day 60 and the mortality rates
were not significantly different between the two study
groups. However, promising results were found in patients
with severe hypoxemia with a lower number of ventilator-
free days at 60 days in the control group [6]. In addition,
Pham and colleagues recently showed, in a cohort of 123
patients with influenza A(H1N1)-induced ARDS, that a
higher plateau pressure on the first day of VV-ECMO for
acute respiratory failure was significantly associated with
ICU death (odds ratio = 1.33, 95% confidence interval =
1.14 to 1.59, P <0.01) [4]. It is worth noting that the ultra-
protective ventilation strategy was associated with the use
of high PEEP levels in all cases [6,18,60].
Using a pressure control approach with tight limitation
of the peak inspiratory pressure between 20 and 25
cmH2O has been suggested to be beneficial [3]. Depend-
ing on the severity of the lung disease, ultra-protective
ventilation with plateau pressure limitation may lead to
apneic ventilation (that is, no tidal volume) for several
days. This may be particularly evident with pediatric pa-
tients [61,62], and in some cases the reduction of the tidal
volume to achieve limited ventilation pressure strategy is
considered so important that the result is insufficient ven-
tilation to maintain adequate oxygen delivery. In this case,
a third venous ECMO cannula to increase ECMO blood
flow may be utilized rather than increasing the inspiratorypressure, which may negate the beneficial effect of the
ECMO. Despite its feasibility reported on animal studies
[63], pediatric studies [64] and in our daily adult practice,
the long-term effect of apneic ventilation is unknown. A
very low tidal volume results in dead space ventilation
only. In our opinion, this must be combined with a high
level of PEEP, to maintain convective ventilation for the
elimination of alveolar nitrogen [63] and avoid alveolar
collapse.
Although there are no large randomized studies focused
on MV settings during ECMO in severe acute respiratory
failure, it is reasonable, at this time, to advise an ultra-
protective ventilation strategy with ECMO, based on a
tidal volume reduction (that is, <4 ml/kg PBW) and on a
plateau pressure reduction (that is, ≤25 cmH2O), provided
lung recruitment with PEEP is sufficient.
For patients without ARDS treated by VA-ECMO,
lung function is often abnormal. Cardiogenic pulmonary
edema, postoperative lung damage and thoracic compli-
ance reduction are frequently present after cardiac sur-
gery, and these patients are at risk of developing ARDS.
Targeting lower tidal volumes (6 to 8 ml/kg PBW) ap-
pears to decrease the incidence of adverse outcome,
even without ARDS [65], and would appear to be rea-
sonable in this population [22], as would a reduction
in the respiratory rate during periods of minimal pul-
monary artery blood flow. In addition, CO2 removal
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volume with less discomfort and dyspnea, and therefore
less sedation – but this is an area for further research.
Mechanical ventilation settings: positive end-expiratory
pressure
It is important to be aware that, despite the use of
ECMO, decreasing tidal volume <4 ml/kg PBW may in-
crease atelectasis and result in severe ventilation/perfu-
sion mismatch unless PEEP is appropriately increased
[66]. Higher PEEP levels are essential [18,19,63] – prob-
ably higher than suggested by the Extracorporeal Life
Support Organization (ELSO) guidelines, which suggest
a modest PEEP of 10 cmH2O [22] – while taking into
account the risk of alveolar overdistension and increased
alveolar strain [44]. In addition, higher PEEP levels, can
also maintain convective ventilation for the elimination
of alveolar nitrogen accumulated during apneic oxygen-
ation with ECMO [63].
High PEEP levels may have an adverse effect on
hemodynamics when the patient is managed in the VV-
ECMO mode by inhibiting venous return [22]. Although
heart function is partially or completely replaced by VA-
ECMO, high PEEP levels might also exacerbate right
ventricular dysfunction and delay heart recovery. Par-
ticular caution and frequent cardiac echography moni-
toring should thus be advised for patients with ARDS
and moderate right failure treated with VV-ECMO.
Mechanical ventilation settings: fraction of inspired
oxygen, respiratory rate
To limit pulmonary oxygen toxicity [52], the ventilator
fraction of inspired oxygen should also be reduced to
the minimal value to keep arterial saturation >85% [23].
Settings for the respiratory rate are debated, with some
authors suggesting that rapid respiratory rates may in-
crease mechanical lung stress [22]. Current expert opin-
ions vary, and a broad range has been suggested from 4
to 30 cycles/minute (Table 1). In our opinion, the re-
spiratory rate must be set to maintain pH and arterial
CO2 partial pressure within normal ranges. A first ap-
proach could thus be to tailor the respiratory rate to the
tidal volume and ECMO gas flow settings.
Mechanical ventilation settings: mode of mechanical
ventilation
To date no study has compared different modes of MV
during ECMO. The choice of mode used during ECMO
must thus be guided by both physician usage pattern
and local resource availability. However, an ultra-
protective strategy should be advocated (Table 1).
The assist-controlled mode in pressure or volume
seems to be commonly used during the initial phase of
ARDS with ECMO, when patients are often deeplysedated and paralyzed and when alterations of lung com-
pliance are greatest. With the target settings discussed
previously, the pressure-controlled mode appears to be
advocated, and is probably the most popular mode in
the initial phase of ARDS with ECMO [3,22]. While
minimizing the potential for VILI with ultra-protective
ventilation, the pressure-controlled mode allows daily
monitoring of the tidal volume increase as the patient’s
condition improves. As the lung compliance improves, it
is possible to see the gradual increase in tidal volume
from very negligible tidal volume (50 ml) to 6 ml/kg
PBW (inferior limit for ECMO weaning) [22]. However,
while pressure control ventilation is advocated, some au-
thors have recommended including spontaneous breathing
to allow diaphragm contraction. Spontaneous breathing in
any phase of the mechanical ventilator cycle is possible
during airway pressure release ventilation, a ventilation
mode that periodically switches between two levels of
continuous positive airway pressure [67]. Combined with
spontaneous breathing, airway pressure release ventilation
appeared to augment the distribution of ventilation to
dependent lung regions [68], to decrease the workload on
the respiratory muscle [69] and to increase systemic blood
flow in patients with severe ARDS [70]. As a result, airway
pressure release ventilation might be an alternative mode
to conventional pressure-controlled MV in ARDS with
ECMO [71,72].
Prolonged controlled ventilation without diaphragmatic
contraction may result in severe atrophy and increased
duration of ventilatory support [73]. The pressure-assisted
mode with spontaneous diaphragm contraction should
therefore be used as soon as possible. Recent case reports
have noticed the successful combination of neurally ad-
justed ventilatory assist and ECMO in patients with se-
verely impaired lung function in the recovery phase
[74,75]. The automated protective ventilation permitted
with this closed-loop ventilation mode [76] may improve
patient–ventilator synchrony, particularly in patients with
ARDS [75].
In the case of patients with hypercapnic respiratory
failure due to chronic obstructive pulmonary disease,
or chronic end-stage respiratory failure treated with VV-
ECMO or ECCO2R, the findings of recent pilot studies
have suggested that the optimal management is to wean
from MV as soon as possible once ECMO has been
established [9,11,77]. In this case, ECMO without inva-
sive MV, named awake ECMO, seems feasible, is rele-
vant and has been associated with good results [9,11,77].
Associated measures
To obtain high-flow ECMO sufficient to perform ultra-
protective ventilation, ECMO cannulas with high diameter
are essential [31]. Similarly, diuresis to dry weight [78] and
restrictive transfusion strategies [31] should be attempted
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sion that may be needed at the initial phase of the disease.
Every effort should then be made to achieve net negative
fluid balance. In addition, tracheotomy is frequently done
safely under ECMO in this population exposed to pro-
longed MV. Sedation and analgesia should be titrated asTable 1 Actual experts’ opinion regarding mechanical ventila
oxygenation
Source Mechanical ventilation settings
ECMO for severe ARDS
ELSO guidelines [22] Reasonable initial ventilator settings during
ECMO could be:
• decelerating flow (pressure control)
• modest PEEP (for example, 10 cmH2O)
• low inflation pressure (for example,
10 cmH2O above PEEP)




Volume assist control mode with:
• PEEP ≥10 cmH2O
• tidal volume reduced to obtain plateau press
to 25 cmH2O
• respiratory rate 6 to 20 cycles/minute
• FiO2 between 30 and 50%
CESAR trial [3] Lung rest settings with:
• peak inspiratory pressure 20 to 25 cmH2O
• PEEP between 10 and 15 cmH2O
• respiratory rate 10 cycles/minute
• FiO2 30%
EOLIA trial [72] Assisted control mode with:
• PEEP ≥10 cmH2O
• tidal volume reduced to obtain plateau press
≤20 cmH2O
• respiratory rate 10 to 30 cycles/minute
• or APRV with:
• high pressure ≤20 cmH2O
• PEEP ≥10 cmH2O
ECMO for cardiac
failure (VA-ECMO)
ELSO guidelines [22] ‘Whether the patient is on either venovenous or v
mode, the ventilator should be managed at low s
allow lung rest’
APRV airway pressure release ventilation, ARDS adult respiratory distress syndrome,
membrane oxygenation, FiO2 Fraction of inspired oxygen, PEEP positive end-expiratlow as possible to conciliate protective ventilation with
comfort and tolerance of the cannula.
Recommendations
Many retrospective studies of patients with ARDS mech-
anically ventilated during ECMO did not provide detailstion management with extracorporeal membrane
Notes
‘These guidelines describe useful and safe practice, but
these are not necessarily consensus recommendations.
These guidelines are not intended as a standard of care …’
Once patients stabilize and sedation can be lightened,
spontaneous ventilation with pressure support ventilation
can be considered
te
These recommendations were done specifically for
patients with H1N1 influenza-induced ARDS
ure ≤20
Multicenter, international, randomized, open trial that
will evaluate the impact on the morbidity and mortality of
ECMO, early instituted after the diagnosis of ARDS with an
unfavorable outcome after 3 to 6 hours despite optimal
ventilatory management and maximum medical treatment.




ELSO Extracorporeal Life Support Organization, ECMO extracorporeal
ory pressure, VA-ECMO venoarterial extracorporeal membrane oxygenation.
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experts in the field in the form of the ELSO guidelines
[22], MV network [24] and protocols from previous [3] or
ongoing [72] prospective randomized trials. For brief MV
management, ELSO recommends ‘reasonable initial venti-
lator settings during extracorporeal life support (ECLS) …
with a respiratory frequency of 4 to 5 per minute, modest
PEEP (e.g. 10 cm H2O), and low inflation pressure
(e.g. 10 cm H2O above PEEP, or a peak inspiratory pres-
sure (PIP) of 20 cm H2O. Once patients are stabilized and
sedation can be lightened, spontaneous ventilation with
pressure support ventilation can be considered’ [22].
Despite current use of heterogeneous modes of MV,
an ultra-protective ventilation strategy for ECMO with
acute respiratory failure is commonly suggested as best
practice (Table 1). To what extent we should reduce
both the tidal volume and the plateau pressure to allow
lung rest remains unknown and is an area for future re-
search. Similarly, the impact of PEEP and tidal volume
on the timing of recovery of heart function in patients
supported with VA-ECMO is unclear and is another im-
portant area of future research.
Evidence gap and future directions
Recent publications have suggested several directions
forward.
No future for invasive mechanical ventilation with ECMO?
In the future, will we still need invasive MV with ECMO
at all? As described previously, invasive MV is a poten-
tial cause of VILI and ventilator-associated pneumonia,
which can further enhance the initial lung damage. Nu-
merous centers have reported the strategy of employing
ECMO as a bridge to lung transplantation [9,80,81]
without invasive ventilation.
A recent pilot study has suggested that ECMO might
be used for hypercapnic respiratory failure in chronic
obstructive pulmonary disease patients as an alternative
to non-invasive ventilation or in the case of non-invasive
ventilation failure [11]. In a proof-of-concept study, 26
patients awaiting lung transplantation who developed
end-stage respiratory failure and were supported with
ECMO while awake (that is, no invasive ventilation)
were retrospectively compared with a historical control
group [9]. The control group was supported with inva-
sive MV as a bridge to lung transplantation. Despite the
same duration of assistance, the 6-month survival after
transplantation was higher in the ECMO group. The
main benefits of awake ECMO were avoiding the com-
plications of prolonged intubation, MV and sedation, as
well as maintaining active physical activity while receiv-
ing ECMO, which may have improved physical fitness
prior to transplantation. The same strategy was also de-
scribed as feasible and safe with VA-ECMO [82]. This isbriefly suggested by the ELSO guidelines as: ‘… An alter-
native is to extubate the patient and allow spontaneous
breathing with the patient awake’ [22].
Recent advances in ECMO technology and a better
understanding of the respiratory drive, in particular the
source of dyspnea and discomfort, might allow the use
of ECMO as an alternative to invasive MV in selected
patients with ARDS [83]. Hoeper and colleagues recently
reported the feasibility of VV-ECMO in six awake, non-
intubated, spontaneously breathing patients with ARDS
[84]. Avoiding mechanical ventilation might be of par-
ticular interest in specific patient populations that are
placed at high risk with invasive ventilation; for example,
patients with immunosuppression or end-stage chronic
lung disease [9,11].
Trials focus on mechanical ventilation strategies with
extracorporeal membrane oxygenation
Description of actual MV management with ECMO
worldwide is warranted to give the basis to design future
interventional trials. For instance, evaluation of the im-
pact of an ultra-protective lung ventilation strategy with
ECMO for ARDS by a large international randomized
trial is now needed.
Monitoring mechanical ventilation settings prior to and
during extracorporeal membrane oxygenation
As blood gas is a mix up of oxygen delivered both from
the ECMO and from the native lung, monitoring the na-
tive lung during ECMO is very scanty. However, simple
beside tools are available. Daily plateau pressure and
compliance monitoring is a first, but imperfect, way to
monitor native lung function. In addition, if a pressure
mode is used, the daily monitoring of the tidal volume
obtained may be valuable information. Although there is
no published evidence, continuous measurement of end-
tidal CO2 is used by some teams to monitor native lung
improvement during the ECMO course. Moreover, MV
during ECMO may lead to overdistension and under-
recruitment depending on the degree of heterogeneity of
regional compliance [44].
Assessment of regional lung mechanics is not easy with
extremely severe ARDS prior to or during ECMO. There-
fore, for technical and safety reasons, thoracic computed
tomography could not be routinely recommended for
these patients. Electrical impedance tomography could be
considered as a MV monitoring tool prior and during
ECMO for ARDS. Some authors have suggested that it
could be a bedside tool to identify patients in whom lung
protection and reversal of hypoxemia is not achievable
with MV (that is, ECMO recipient), or to identify patients
who would benefit from MV with lung recruitment
maneuvers (that is, ECMO nonrecipient) [85]. Similarly,
Grasso and colleagues suggested the use of transpulmonary
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to assess physiological titration of PEEP [86]. Indeed, the
authors demonstrated that 50% of patients with influenza
A(H1N1)-associated ARDS referred to their unit for
ECMO did not receive ECMO, because the transpulmon-
ary pressure was lower than airway pressure alone. This
unexpected lower value, mainly due to low chest wall
compliance, allowed a safe increase in the PEEP level,
which in turn increased oxygenation and avoided the use
of ECMO. This individually tailored approach could be
the future direction of research to select the ‘best’ candi-
dates for ECMO, if used as a rescue therapy for severe
acute hypoxemic respiratory failure.
Conclusions
Although the positive impact of a protective lung venti-
lation strategy on survival in ARDS has been clearly
demonstrated, in patients receiving MV during ECMO
there is limited evidence to guide practice. Based on ac-
tual and past randomized trials of ARDS with ECMO,
an ultra-protective ventilation strategy that limits tidal
volume to <4 ml/kg PBW, targets a very low plateau pres-
sure (<25 cmH2O) and is supported by increased alveolar
recruitment with PEEP may be the best option for clini-
cians managing these critically ill patients. As the use of
ECMO increases internationally, future studies are ur-
gently required to determine the best practice of MV dur-
ing ECMO and its impact on patient-centered outcomes.
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